<code id='E7CCE73E1D'></code><style id='E7CCE73E1D'></style>
    • <acronym id='E7CCE73E1D'></acronym>
      <center id='E7CCE73E1D'><center id='E7CCE73E1D'><tfoot id='E7CCE73E1D'></tfoot></center><abbr id='E7CCE73E1D'><dir id='E7CCE73E1D'><tfoot id='E7CCE73E1D'></tfoot><noframes id='E7CCE73E1D'>

    • <optgroup id='E7CCE73E1D'><strike id='E7CCE73E1D'><sup id='E7CCE73E1D'></sup></strike><code id='E7CCE73E1D'></code></optgroup>
        1. <b id='E7CCE73E1D'><label id='E7CCE73E1D'><select id='E7CCE73E1D'><dt id='E7CCE73E1D'><span id='E7CCE73E1D'></span></dt></select></label></b><u id='E7CCE73E1D'></u>
          <i id='E7CCE73E1D'><strike id='E7CCE73E1D'><tt id='E7CCE73E1D'><pre id='E7CCE73E1D'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:leisure time    - browse:73793
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time